Targeting survivin in cancer: the cell-signalling perspective
| Autor: | Rupinder K. Kanwar, Jagat R. Kanwar, Sishir K Kamalapuram |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
MAPK/ERK pathway
Cell signaling Survivin Antineoplastic Agents Inhibitor of Apoptosis Proteins law.invention Drug Delivery Systems law Neoplasms Drug Discovery Animals Humans Medicine PTEN Protein kinase B PI3K/AKT/mTOR pathway Pharmacology biology business.industry Cancer medicine.disease Immunology Cancer research biology.protein Suppressor business Signal Transduction |
| Zdroj: | Drug Discovery Today. 16:485-494 |
| ISSN: | 1359-6446 |
| DOI: | 10.1016/j.drudis.2011.04.001 |
| Popis: | Survivin, a prominent anticancer target, is ubiquitously expressed in a plethora of cancers and the evolving complexity in functional regulation of survivin is yet to be deciphered. However, pertaining to the recent studies, therapeutic modulation of survivin is critically regulated by interaction with prominent cell-signalling pathways [HIF-1α, HSP90, PI3K/AKT, mTOR, ERK, tumour suppressor genes (p53, PTEN), oncogenes (Bcl-2, Ras)] and a wide range of growth factors (EGFR, VEGF, among others). In our article we discuss, in detail, an overview of the recent developments in the pharmacological modulation of survivin via cell-signalling paradigms and antisurvivin therapeutics, along with an outlook on therapeutic management of survivin in drug-resistant cancers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect